A Crystallographic-Based Fragment Screen Against Human BRD4 Bromodomain 1
Poster Oct 17, 2012
Hubbard P, Ritchie A, Hughes S, Lipkin M, Blackaby W & MacLeod A
Given that DMSO is a well known competitor of compound binding in human BRD4 bromodomain 1, we initially solved the crystal structure of this protein soaked in the presence of DMSO. Confirming that DMSO binds to the acetyllysine binding site, we commenced the fragment screen using ethanol as the compound solvent, allowing solvent to evaporate before solutions for protein crystal soaks were prepared. Fragments were batched into groups of three based on shape diversity and chemical compatibility, and datasets from soaked crystals that spanned the entire fragment library were collected using in-house X-ray diffraction equipment.
This poster presents a summary of the results, demonstrating how Biofocus’s structural biology capabilities complement their range of fragment screening services.
Exploiting Polypharmacology in Precision Oncology: Identification of Differential Kinase Off-targets Among Clinical PARP InhibitorsPoster
Can we use computational methods to identify previously unknown off-targets of PARP inhibitors that can explain their observed differences?READ MORE
Bioluminescent Assay for GTPases Allows Measurement of GTPase, GAP and GEF ActivitiesPoster
We have developed a homogenous bioluminescent assay (GTPase-Glo) system to analyze these proteins in a simple, convenient “add-mix-read” format.READ MORE
Fc Effector Bioassays for Rapid and Quantitative Measurement of ADCC and ADCP Mechanisms of ActionPoster
Drug developers are rapidly adopting Fc effector function reporter-based bioassays to measure antibody Fc functions such as ADCC and ADCP activity during the development of therapeutic antibodies. Here we show application of a suite of FcgR Reporter Bioassays to elucidate and characterize antibody MOA.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018